Innovative leukaemia treatment with tcxpress platform
Drug Target Review
SEPTEMBER 7, 2023
The first clinical candidate, BSB-1001, aims to transform leukemia treatment by targeting minor histocompatibility antigen-1. This two-part therapy aligns with allogeneic hematopoietic stem cell transplantation to enhance patient outcomes. The company is on track to file an IND in Q4 of 2023.
Let's personalize your content